The COVID-19 resource centre, created by Elsevier, provides free information in English and Mandarin on the novel coronavirus. Elsevier grants permission to make all its COVID-19-related research available in PubMed Central and other public repositories, with unrestricted access for research reuse and analysis, provided that the original source is acknowledged. The article "Insights into SARS-CoV-2 genome, structure, evolution, pathogenesis and therapies: Structural genomics approach" by Ahmad Abu Turab Naqvi et al. reviews the differences in genomic, proteomic, pathogenesis, and therapeutic strategies of SARS-CoV-2 compared to SARS-CoV and MERS-CoV. The study highlights the structural analysis of drug target proteins, cytokine profiling, and inflammatory pathways. The authors suggest that minimal variations in the genome sequence of SARS-CoV-2 may lead to significant structural changes in target proteins, rendering previously effective drugs ineffective. The article also discusses the molecular basis of pathogenesis, including the role of innate and adaptive immune systems, and the impact of the renin-angiotensin-aldosterone system (RAAS) on SARS-CoV-2 infection. It reviews potential drug targets, such as the spike glycoprotein (S), envelope protein (E), membrane protein (M), nucleoprotein (N), and replicase polyprotein, and their structural and functional characteristics. The authors compare the structural similarities and differences between SARS-CoV-2 and other coronaviruses, emphasizing the importance of understanding these differences for drug and vaccine development. Therapeutic approaches, including drug repurposing and in silico methods, are discussed, along with the use of anti-inflammatory drugs and monoclonal antibodies. The article highlights the effectiveness of remdesivir and chloroquine in inhibiting SARS-CoV-2, but notes the need for further clinical trials to confirm their efficacy.The COVID-19 resource centre, created by Elsevier, provides free information in English and Mandarin on the novel coronavirus. Elsevier grants permission to make all its COVID-19-related research available in PubMed Central and other public repositories, with unrestricted access for research reuse and analysis, provided that the original source is acknowledged. The article "Insights into SARS-CoV-2 genome, structure, evolution, pathogenesis and therapies: Structural genomics approach" by Ahmad Abu Turab Naqvi et al. reviews the differences in genomic, proteomic, pathogenesis, and therapeutic strategies of SARS-CoV-2 compared to SARS-CoV and MERS-CoV. The study highlights the structural analysis of drug target proteins, cytokine profiling, and inflammatory pathways. The authors suggest that minimal variations in the genome sequence of SARS-CoV-2 may lead to significant structural changes in target proteins, rendering previously effective drugs ineffective. The article also discusses the molecular basis of pathogenesis, including the role of innate and adaptive immune systems, and the impact of the renin-angiotensin-aldosterone system (RAAS) on SARS-CoV-2 infection. It reviews potential drug targets, such as the spike glycoprotein (S), envelope protein (E), membrane protein (M), nucleoprotein (N), and replicase polyprotein, and their structural and functional characteristics. The authors compare the structural similarities and differences between SARS-CoV-2 and other coronaviruses, emphasizing the importance of understanding these differences for drug and vaccine development. Therapeutic approaches, including drug repurposing and in silico methods, are discussed, along with the use of anti-inflammatory drugs and monoclonal antibodies. The article highlights the effectiveness of remdesivir and chloroquine in inhibiting SARS-CoV-2, but notes the need for further clinical trials to confirm their efficacy.